Costa Rica introduces two new vaccines into the national immunization program

Costa Rica
16 October 2017

October 2017 marks the introduction of the rotavirus and human papillomavirus (HPV) vaccines in Costa Rica’s immunization program. This decision results from the recommendations of the country National Immunization Technical Advisory Group (NITAG). Since 2001, Costa Rica’s NITAG, which is called Comisión Nacional de Vacunación y Epidemiología (National Commission on Vaccination and Epidemiology), is in charge of establishing and periodically updating the national immunization schedule as well as formulating overall policies and strategies for immunization. In order to issue the recommendations, the NITAG conducted cost-effectiveness studies that were then approved by its members.


The rotavirus vaccine will be administered to children younger than 8 months, while the HPVvaccine will be administered to 10-year-old girls.

"With the introduction of these vaccines in the official vaccination schedule, we now have one of the most complete vaccination schedules in the region. And this will result in the health of the population, reducing disease burden caused by rotavirus and HPV, as well as decreasing the incidence of cervical cancer in the medium and long term," stated the Coordinator of Immunizations and NITAG secretary, Dr. Roberto Arroba Tijerino.

The rotavirus vaccine will be purchased next year with a budget from the Ministry of Health; the vaccine will be donated to the Costa Rican Department of Social Security, which will be responsible for vaccine administration. It is estimated that the vaccination program will start after arrival of the vaccine in the country in mid-2018. Since Costa Rica’s Immunization Law passed in 2001, the entire population recieves free access to immunization and the law requires both the Ministry of Health and the Costa Rican Department of Social Security to ensure sufficient amounts in their budgets to purchase vaccines and cover the costs of the program. The rotavirus vaccine is being purchased through the Pan American Health Organization Revolving Fund.

The date of introduction of the HPV vaccine remains to be determined. It is estimated that it could be incorporated into the official country immunization schedule  by 2019.

Related News & Events

  • Kazakhstan

    Voice from the field : Lyazzat Yeraliyeva


    The NITAG of Kazakhstan recently launched their website to make their recommendations available and promote the work of the members. Lyazzat Yeraliyeva, former Chair of the NITAG, now acts as the Deputy Chair.

    Read more
  • NITAGs

    Strenghtening NITAGs through the Partnership for Influenza Vaccine Introduction


    The Partnership for Influenza Vaccine Introduction (PIVI), based at The Task Force for Global Health (TFGH), is an innovative public/private program that partners with the Centers for Disease Control and Prevention (CDC), Ministries of Health, corporate partners and others to create sustainable, routine, seasonal influenza vaccination programs in low- and middle-income countries.   PIVI’s goal is to create routine, seasonal influenza vaccination programs to protect communities from the impacts of both seasonal and pandemic influenza. Working with countries’ Ministries of Health, as well as with other technical collaborators, PIVI supports capacity building for NITAGs to make evidence-based vaccine policy decision making.  These activities are coordinated with NITAG strengthening work carried out through other projects and cooperative funding agreements between countries and CDC’s Influenza and Global Immunization Divisions.  The work is also closely coordinated with NITAG focal points in WHO regional and country offices.  

    Read more
  • Netherlands

    The Health Council of the Netherlands recommends rotavirus vaccination for children despite not being cost-effective


    Rotavirus infections cause thousands of hospitalisations a year amongst young children. Vaccination can prevent a large part of these, as well as almost completely banishing mortality from rotavirus. These benefits outweigh the small risk of a serious complication from vaccination, according to the Health Council.

    Read more